ArticleClinical and experimental medicine2014
Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells.
Article in Clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Article
- Review
- Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease.Disease models & mechanisms · 2020Article
- Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.Journal of ovarian research · 2019Article
- Probiotic effect onExperimental and therapeutic medicine · 2019Article
- Antihypertensive Effects of Corn Silk Extract and Its Novel Bioactive Constituent in Spontaneously Hypertensive Rats: The Involvement of Angiotensin-Converting Enzyme Inhibition.Molecules (Basel, Switzerland) · 2019Article
- Article
- Influence of H. pylori CagA Coupled with Alcohol Consumption on Cytokine Profiles in Men.Medicine · 2016Observational
- Article
- Helicobacter pylori and interleukin-8 in gastric cancer.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection of gastric epithelial cells by Helicobacter pylori stimulates the activation of nuclear factor-κB (NF-κB) and the upregulation of interleukin-8 (IL-8) expression. Activation of NF-κB can occur through classical (p50/p65) and alternative (p52/RelB) pathways. The role of the bacterial cag pathogenicity island (PAI) in these events is controversial. This study aimed to evaluate the hypothesis that the CagA protein is required for H. pylori-induced activation of NF-κB and upregulation of IL-8 expression, and for clarithromycin (CAM) to exert its molecular effects. Cultured KATO-III human gastric cancer cells were treated with extracts of H. pylori strains ATCC43504 (cag PAI(+)) and ATCC51932 (cag PAI(-)) for 24 h. NF-κB and phospho-IκB protein expression was then evaluated using western blotting. IL-8 mRNA expression was evaluated using the reverse transcription polymerase chain reaction. Following the separation of the proteins using two-dimensional gel electrophoresis, proteomes of the two bacterial extracts were compared using nanoflow liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) analysis. Although the protein profiles of the two extracts differed, both extracts induced IκBα phosphorylation, upregulation of IL-8 expression, and NF-κB activation through classical and alternative pathways. In cells treated with either of the bacterial extracts, CAM inhibited H. pylori-induced activation of NF-κB and upregulation of IL-8 expression. These results suggested that CagA is not required for H. pylori-induced activation of NF-κB and upregulation of IL-8 expression in gastric epithelial cells. H. pylori-induced NF-κB signaling can occur through classical and alternative activation pathways, and that CAM inhibits these two pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.